COVID-19 outcomes in people with cystic fibrosis.
Journal
Current opinion in pulmonary medicine
ISSN: 1531-6971
Titre abrégé: Curr Opin Pulm Med
Pays: United States
ID NLM: 9503765
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
entrez:
8
10
2021
pubmed:
9
10
2021
medline:
15
10
2021
Statut:
ppublish
Résumé
The COVID-19 global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a dramatic impact that is still ongoing around the world. Cystic fibrosis (CF) has been identified as a possible risk factor of poor outcome. Data collected by multiple National CF registries around the world have indicated that persons with CF (PwCF) are not more likely to be affected by SARS-CoV-2 than the general population. The course of SARS-CoV-2 is usually mild in PwCF who are relatively young. Severe outcomes have been described in patients with low lung function and in those with immune suppression (i.e. solid organ transplantation). Indirect impact of the pandemic on the CF community has also been observed, including difficulties in the organization of CF care, leading to a dramatic increase in telehealth for PwCF. The pandemic has further affected clinical research by complicating ongoing clinical trials. Vaccination appears important to all PwCF, with special priority on developing adequate vaccination scheme for transplant recipients. Long-term effects of COVID-19 on the CF population remains unknown. The COVID-19 pandemic has caused significant impacts on PwCF and on healthcare professionals who provide specialized CF care and clinical research.
Identifiants
pubmed: 34620788
doi: 10.1097/MCP.0000000000000823
pii: 00063198-202111000-00009
pmc: PMC8575136
mid: NIHMS1749719
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
538-543Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK089507
Pays : United States
Organisme : NHLBI NIH HHS
ID : UM1 HL119073
Pays : United States
Organisme : FDA HHS
ID : R01 FD003704
Pays : United States
Organisme : FDA HHS
ID : R01 FD006848
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000423
Pays : United States
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727–733.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506.
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323:2052–2059.
Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region: case series. N Engl J Med 2020; 382:2012–2022.
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–1062.
Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397:220–232.
Zheng KI, Feng G, Liu WY, et al. Extrapulmonary complications of COVID-19: a multisystem disease? J Med Virol 2020; 93:323–335.
Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020; 395:1763–1770.
Shetty AA, Tawhari I, Safar-Boueri L, et al. COVID-19-associated glomerular disease. J Am Soc Nephrol 2021; 32:33–40.
Lenhart-Pendergrass PM, Anthony M, Sariyska S, et al. Detection of bacterial pathogens using home oropharyngeal swab collection in children with cystic fibrosis. Pediatr Pulmonol 2021; 56:2043–2047.
Dixon E, Dick K, Ollosson S, et al. Telemedicine and cystic fibrosis: do we still need face-to-face clinics? Paediatr Respir Rev 2021; doi: 10.1016/j.prrv.2021.05.002 [Online ahead of print].
doi: 10.1016/j.prrv.2021.05.002
Perkins RC, Davis J, NeSmith A, et al. Favorable clinician acceptability of telehealth as part of the cystic fibrosis care model during the COVID-19 pandemic. Ann Am Thorac Soc 2021; S1526-0542(21)00054-3. doi: 10.1016/j.prrv.2021.05.002. [Online ahead of print].
doi: 10.1016/j.prrv.2021.05.002.
Colombo C, Burgel PR, Gartner S, et al. Impact of COVID-19 on people with cystic fibrosis. Lancet Respir Med 2020; 8:e35–e36.
Viviani L, Assael BM, Kerem E. ECFS (A) H1N1 study group. Impact of the A (H1N1) pandemic influenza (season 2009–2010) on patients with cystic fibrosis. J Cyst Fibros 2011; 10:370–376.
Ramos KJ, Pilewski JM, Faro A, Marshall BC. Improved prognosis in cystic fibrosis: consideration for intensive care during the COVID-19 pandemic. Am J Respir Crit Care Med 2020; 201:1434–1435.
Cosgriff R, Ahern S, Bell SC, et al. A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. J Cyst Fibros 2020; 19:355–358.
Bain R, Cosgriff R, Zampoli M, et al. Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: an international observational study. J Cyst Fibros 2021; 20:25–30.
Scagnolari C, Bitossi C, Frasca F, et al. No detection of SARS-CoV-2 in cystic fibrosis patients at the Regional (Lazio) Reference Center for CF in Italy. J Cyst Fibros 2020; 19:837–838.
Berardis S, Verroken A, Vetillart A, et al. SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis. J Cyst Fibros 2020; 19:872–874.
Stanton BA, Hampton TH, Ashare A. SARS-CoV-2 (COVID-19) and cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2020; 319:L408–L415.
Corvol H, de Miranda S, Lemonnier L, et al. First wave of COVID-19 in French patients with cystic fibrosis. J Clin Med 2020; 9:3624doi: 10.3390/jcm9113624.
doi: 10.3390/jcm9113624
Mondejar-Lopez P, Quintana-Gallego E, Giron-Moreno RM, et al. Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: incidence and results of the national CF-COVID19-Spain survey. Respir Med 2020; 170:106062.
McClenaghan E, Cosgriff R, Brownlee K, et al. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. J Cyst Fibros 2020; 19:868–871.
Naehrlich L, Orenti A, Dunlevy F, et al. Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020. J Cyst Fibros 2021.
Farfour E, Picard C, Beaumont L, et al. COVID-19 in lung-transplanted and cystic fibrosis patients: be careful. J Cyst Fibros 2020; 19:e16–e17.
Messika J, Eloy P, Roux A, et al. COVID-19 in lung transplant recipients. Transplantation 2021; 105:177–186.
Semenzato L, Botton J, Drouin J, et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet Reg Health Eur 2021; 8:100158.
Olcese C, Casciaro R, Pirlo D, et al. SARS-CoV-2 and Burkholderia cenocepacia infection in a patient with cystic fibrosis: an unfavourable conjunction? J Cyst Fibros 2021; 20:e29–e31.
Patel S, Thompson MD, Slaven JE, et al. Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic. Pediatr Pulmonol 2021; 56:1271–1273.
Havermans T, Houben J, Vermeulen F, et al. The impact of the COVID-19 pandemic on the emotional well being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients. J Cyst Fibros 2020; 19:880–887.
Westcott KA, Wilkins F, Chancellor A, et al. The impact of COVID-19 shielding on the wellbeing, mental health and treatment adherence of adults with cystic fibrosis. Future Healthc J 2021; 8:e47–e49.
Radtke T, Haile SR, Dressel H, Benden C. Recommended shielding against COVID-19 impacts physical activity levels in adults with cystic fibrosis. J Cyst Fibros 2020; 19:875–879.
Fernandez-Del-Valle M, Donadio MVF, Pérez-Ruiz M. Physical exercise as a tool to minimize the consequences of the Covid-19 quarantine: an overview for cystic fibrosis. Pediatr Pulmonol 2020; 55:2877–2882.
Davies J. The coronavirus pandemic has forced rapid changes in care protocols for cystic fibrosis. Nature 2020; 583:S15.
Graziano S, Boldrini F, Righelli D, et al. Psychological interventions during COVID pandemic: telehealth for individuals with cystic fibrosis and caregivers. Pediatr Pulmonol 2021; 56:1976–1984.
Jaclyn D, Andrew N, Ryan P, et al. Patient and family perceptions of telehealth as part of the cystic fibrosis care model during COVID-19. J Cyst Fibros 2021; 20:e23–e28.
Hasan S, Cecilia Lansang M, Salman Khan M, Dasenbrook E. Managing cystic fibrosis related diabetes via telehealth during COVID-19 pandemic. J Clin Transl Endocrinol 2021; 23:100253.
Loupy A, Aubert O, Reese PP, et al. Organ procurement and transplantation during the COVID-19 pandemic. Lancet 2020; 395:e95–e96.
Picard C, Le Pavec J, Tissot A. Impact of the Covid-19 pandemic and lung transplantation program in France. Respir Med Res 2020; 78:100758.
Burgel PR, Durieu I, Chiron R, et al. Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease. Am J Respir Crit Care Med 2021.
van Koningsbruggen-Rietschel S, Dunlevy F, Bulteel V, et al. SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network. Eur Respir J 2020; 56:
Pearson K, Mayer-Hamblett N, Goss CH, et al. The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network. J Cyst Fibros 2021; 20:195–197.
Carr SB, Cosgriff R, Harutyunyan S, et al. COVID-19 vaccine prioritisation for people with cystic fibrosis. J Cyst Fibros 2021.
Ortiz JR, Neuzil KM, Victor JC, et al. Predictors of influenza vaccination in the Cystic Fibrosis Foundation patient registry, 2006 through 2007. Chest 2010; 138:1448–1455.
So AD, Woo J. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis. BMJ 2020; 371:m4750.
Narasimhan M, Mahimainathan L, Clark AE, et al. Serological response in lung transplant recipients after two doses of SARS-CoV-2 mRNA vaccines. Vaccines (Basel) 2021; 9:
Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med 2021; 27:626–631.
Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open 2021; 4:e210830.
Morin L, Savale L, Pham T, et al. Writing Committee for the COMEBAC Study Group. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA 2021; 325:1525–1534.
Carfi A, Bernabei R, Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324:603–605.